代表性论文:
1) Zhu W, Qin Y, Han Y, Qi G, Zeng Q, Song L, Li Z, Deng H, Deng X, Yi K, Yang W, Wang Y, Chen X, Lu H*. A RGD-directed melittin/anti-41BB dual-lock prodrug safely reinvigorates robust anti-tumor immunity. Mol Ther. 2026 Oct 8:S1525-0016(26)00860-9. Doi: 10.1016/j.ymthe.2026.09.041.
2) Song L, Qi G, Shi W, Zeng Q, Qin Y, Wang Z, Li W, Song Z, Zhang A*, Lu H*. A universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44+CD8+ T cells in tumor-draining lymph nodes to enhance antitumor immunity. J ImmunoTher Cancer. 2025 Jul 31; 13(7):e011944. Doi: 10.1136/jitc-2025-011944.
3) Shi W#, Xu W#, Song L, Zeng Q, Qi G, Qin Y, Li Z, Liu X, Jiao Z, Zhao Y, Liu N*, Lu H*. A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses. Mol Ther 2024. 2024 Dec 4;32(12):4482-4496. Doi:10.1016/j.ymthe.2024.10.021
4) Shi W, Liu N, Liu Z, Yang Y, Zeng Q, Wang Y, Song L, Hu F, Fu J, Chen J, Wu M, Zhou L, Zhu F, Gong L, Zhu J, Jiang L*, Lu H*. Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell Rep Med. 2024 May 21;5(5):101531. Doi: 10.1016/j.xcrm.2024.101531.
5) Zhu W, Wang Y, Lv L, Wang H, Shi W, Liu X, Zhou M, Zhu J, Lu H*. Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy. Acta Pharm Sin B. 2023 May 13(5): 2071-2085. Doi: 10.1016/j.apsb.2023.02.004.
6) Shi W, Lv L, Liu N, Wang H, Wang Y, Zhu W, Liu Z, Zhu J, Lu H*. A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity. Mol Ther. 2023 Jan 4;31(1):66-77. Doi: 10.1016/j.ymthe.2022.08.016.
7) Lu H, Zhu S, Qian L, Xiang D, Zhang W, Nie A, Gao J, Wu M, Gao J, Lu B, Yu Y, Han W, Moldenhauer A. Activated expression of the chemokine Mig after chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity. Blood 2012; May 24;119(21):4868-77. Doi: 10.1182/blood-2011-07-367581.